Small Cap Value Report (Fri 16 Feb 2024) - GLE, POS
Good morning from Paul!
Explanatory notes -
A quick reminder that we don’t recommend any stocks. We aim to review trading updates amp; results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it’s anybody’s guess what direction market sentiment will take amp; nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.
We stick to companies that have issued news on the day, with market caps (usually) between £10m and £1bn. We usually avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).
A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed – please be civil, rational, and include the company name/ticker, otherwise people won’t necessarily know what company you are referring to.
What does our colour-coding mean? Will it guarantee instant, easy riches? Sadly not! Share prices move up or down for many reasons, and can often detach from the company fundamentals. So we’re not making any predictions about what share prices will do.
Green (thumbs up) – means in our opinion, a company is well-financed (so low risk of dilution/insolvency), is trading well, and has a reasonably good outlook, with the shares reasonably priced. OR it’s such deep value that we see a good chance of a turnaround, and think that the share price might have overshot on the downside.
Amber – means we don’t have a strong view either way, and can see some positives, and some negatives. Often companies like this are good, but expensive.
Red (thumbs down) – means we see significant, or serious problems, so anyone looking at the share needs to be aware of the high risk. Sometimes risky shares can produce high returns, if they survive/recover. So again, we’re not saying the share price will necessarily under-perform, we’re just flagging the high risk.
Links:
Paul amp; Graham’s 2024 share ideas - live price-tracking spreadsheet (2 separate tabs at bottom),
Frozen SCVR summary spreadsheet for calendar 2023.
New SCVR summary spreadsheet from July 2023 onwards.
Paul’s podcasts (weekly summary of SCVRs amp; macro views) – or search on any podcast provider for “Paul Scott small caps” – eg Apple, Spotify.
Quiet for news again today, so I’ll do a few catch up items -
Other mid-morning movers (with news) -
Fiske (LON:FKE) - up 29% to 60p (£7m) – Interims from this tiny wealth mgt company. £429k PBT in H1, much improved on LY. Strong bal sheet, with £4.1m net cash. Upbeat commentary. Investment in “Euroclear”. This actually looks quite interesting, worth a closer look for microcap investors.
Audioboom (LON:BOOM) – up 8% to 258p (£42m) – Non-regulatory RNS Reach, trumpets growth in audience numbers for its podcasts. 38.6m monthly downloads in Jan 2024, up 9% on Q4 2023 average. See our archive for the negatives too, including expensive mistakes made on legacy contracts, and mgt greed.
Summaries
MJ GLEESON (LON:GLE) – down 1% to 496p (£289m) – H1 Results – Paul – AMBER/GREEN
Interim results to Dec 2023 are poor, as expected, but trading is in line with recently lowered expectations FY 6/2024. Not the amazing bargain it was a year ago, but still good value in my opinion. Share price is 100% backed by tangible net assets. As with other housebuilders, the outlook comments suggest the housing market is beginning to recover.
Plexus Holdings (LON:POS) (Paul holds) – 15p (pre-market) £16m – £1m contract win – Paul – GREEN
I’m biased, as this is by far my largest personal portfolio position, but hopefully I’m still being objective, or trying to anyway. A £1m contract win announcement today is significant as it’s in the plug amp; abandonment area, which Plexus has been saying offers plenty of opportunities in the N.Sea especially. Contract wins need to keep flowing, but this is a positive step forward I think. Risk of dilution has greatly reduced, given $5.2m cash received from SLB recently for a perpetual licence for use in non-core areas. Higher risk, so not for widows or orphans.
Paul’s Section: MJ GLEESON (LON:GLE)
Down 1% y’day to 496p (£289m) – H1 Results – Paul – AMBER/GREEN
Results for the half year ended 31 December 2023
“The results for the half year reflect a robust performance given conditions in the housing market during 2023. Gleeson Homes entered the second half of the year with a strong forward order book and we are seeing encouraging signs of recovery in reservation rates.
We’ve reviewed this affordable housing builder many times in recent years. The big discount to NTAV, and more defensive characteristics of building low cost housing, persuaded me to add Gleesons to my top 20 share ideas for 2023. Despite considerably uncertainty at the time, this idea is now looking good at +44% since the start of 2023, with our entry price being luckily at the 5-year low.
Despite a strong rise in share price, the 5-year chart is making me wonder if this could be the early stages of a new bull run? Particularly as GLE has such a strong balance sheet (like most other housebuilders) that it didn’t need to issue fresh equity either during the pandemic, or in the energy/cost of living/Truss/interest rates crises.
GLE did however blot its copy book recently, with a profit warning which I reviewed here on 9 Jan 2024, Liberum slashed forecast EPS for FY 6/2024 by 22% and by 26% for FY 6/2025, yet amazingly this didn’t seem to trouble the market much, if at all.
GLE did have a big discount to NTAV, but that has now been eradicated by the share price rise, and the StockReport shows shares now trading at about par with NTAV – which is actually still quite attractive, given that it seems likely we’re entering the start of an improvement in housing market transactions again, and household nominal incomes are in some cases 15-20% higher than they were 2 years ago. Which means that more people can afford to, and probably are regaining the confidence to think about buying an affordable new starter home.
H1 results (Dec 2023), key numbers -
Revenue down 11.4% to £151.5m
Profit before tax down 55% to £7.2m
Basic EPS down 56% to 9.6p
H1 divi down 20% to 4.0p
Broker consensus seems to be 33.7p EPS for FY 6/2024, implying a significant H2 bias, given that H1 was only 9.6p EPS.
At 496p/ share, the PER is 14.7x, which isn’t cheap, but we could be looking at earnings being at or near the low point in the cycle, but nobody knows for sure. Hence PERs do tend to look highish at a cyclical low for earnings.
Balance sheet – as is the sector norm at the moment, the balance sheet is ludicrously strong, and hardly has any gearing. Net debt was only £18.7m.
NAV of £287m becomes NTAV of £287m, because there are no intangible assets on the balance sheet. This is almost identical to the £289m market cap, so owning shares in GLE means it’s fully asset-backed. The big asset being inventories of £358m – being houses under construction, plus land, most of which should turn into cash within a reasonable timescale, likely to produce a profit on top of the book cost.
Paul’s opinion - I think GLE still looks very good risk:reward. Buyers in early 2023 have made a very nice profit to date, which they deserve for taking a perceived risk when everyone else was in panic mode, but they were actually buying pound notes for 70p! (the discount to NTAV at the time).
I think the easy money has maybe been made now, but with the housing market cycle now clearly on an improving trend, which we’re hearing from everyone in the sector, I think picking up GLE shares at par with NTAV still looks an attractive option, for more patient investors maybe?
I had a wobble when the profit warning hit on 9/1/2024, dipping to amber to be on the safe side. However, skimming these latest numbers amp; narrative, it strikes me as reassuring. Also I think the desperate need for affordable housing, and likely stimulus measures from whoever is running the country going forwards, combined with inflation now being down to 4% and lower interest rates seeming quite likely, which is good for housing affordability, I think I’ll move up a notch to AMBER/GREEN. Not as cheap as it was, but this still looks an attractive, and I think pretty safe share to consider for further, deeper research. The sector has had a very nice rebound in the last 3 months, so I don’t know what immediate upside there might be, or whether these shares might need to consolidate for a while? That’s more a consideration for traders, than for my reviews of the fundamentals here.
Plexus Holdings (LON:POS) (Paul holds)
15p (pre-market) £16m – £1m contract win – Paul – GREEN
As mentioned before, this is by far my largest personal portfolio holding, so obviously that makes me heavily biased (but hopefully still objective).
Good news to have a decent-sized £1m+ contract win announced today. Note that revenues in recent years have only been c.£2m pa, so a £1m contract win today is quite material to the historical numbers.
I assume this is another rental + services deal, as it mentions the contract starting for 9 months from Q2 (calendar, I assume) 2024. The company has said before that contracts often expand once they start, as happened with the special contract which was initially announced as £5m, but soon grew to £8m (this was the trigger for me buying into POS shares last summer). So maybe this latest deal might also expand? Who knows, that’s just me speculating.
Plexus have been saying for a while that they see big opportunities in plug amp; abandonment of expired oil/gas wells, a growing area, so I feel that today’s news confirms amp; validates what it’s being saying.
I don’t fully understand how this contract links to the SLB deal, does anyone know?
“Exact™ Adjustable Wellheads and Centric Mudline Systems are part of the Plexus licence/collaboration agreement with SLB…”
Once again, this news reinforces my view that Plexus is proven tech, and the company is coming alive again, due to demand driven by methane leak becoming a big environmental issue, and also it seems Plexus is making progress in Pamp;A.
All for £16m market cap, and with the cash situation sorted out, with only 5% dilution from the sale of treasury shares.
Management have protected small shareholders from what could easily have been ruinous dilution, using their own money.
There are useful research notes from Cavendish, available on Research Tree, for more information. Due to 2 large one-off deals, it is forecasting revenues to rise almost 10x in FY 6/2024, and after years of losses, a return to profit of £3.5m. That’s obviously why the shares have multibagged in the last year.
Not for widows amp; orphans that’s for sure, but the company is now in a very much better position today than it was a year ago, with net cash now.
Very volatile share price, indicates that the market doesn’t really know how to value this share yet -
Low StockRank, as I would expect from a company that has generated multi-year losses. Although that should change when the (forecast to be £3.5m profit) FY 6/2024 results are published in the autumn.
Zooming out, the company’s heyday saw it valued at c.£300m (and with a similar number of shares in issue as today). I can remember writing about Plexus here c.10 years ago, but dropped coverage once industry amp; political headwinds saw oil amp; gas exploration in the N.Sea dry up in 2015-16 -
Source: https://www.stockopedia.com/content/small-cap-value-report-fri-16-feb-2024-gle-pos-989522/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
![Report abuse](/img/report_abuse.png)